Featured in Forbes, Vella Bioscience CEO Carolyn Wheeler discusses the next frontier in women’s health and why one of the largest unmet needs extends far beyond sexual wellness. After building Vella Bioscience around products designed to support female arousal and orgasm, Wheeler and her team identified a much larger gap: the lack of clinically validated solutions for women experiencing vulvovaginal pain and discomfort. The article highlights the launch of Ebbtide, a science-backed product developed to address a condition affecting millions of women who often have few effective treatment options.
The Forbes feature explores how Vella Bioscience is helping shift women’s health from an underserved wellness category to one grounded in clinical research, scientific rigor, and measurable outcomes. By focusing on conditions that have historically received limited attention and investment, Wheeler is working to expand access to evidence-based solutions while helping reshape the broader conversation around women’s health, innovation, and quality of life.
